Sign in with Google
China TCM (570.HK) - Updates on Performance Forecast and Valuation Outlook Based on 2024 Results
Xinyao has highlighted this Insight as a Top Pick
522 Views02 Apr 2025 00:55
2024 would be the performance low point for China TCM, but performance is expected to recover from 2025 and on onwards. Investors can consider buying on dips when market value is below RMB10 billion.
What is covered in the Full Insight:
- Introduction to China TCM's Performance
- Detailed Financial Results of 2024
- Factors Behind Financial Decline
- Positive Developments and Outlook
- Forecast and Investment Considerations
Boomeranged on Wed, 9 Apr 2025 00:57
CNPGC increased its stake in China TCM at an average price of HK$1.86/share in light of its confidence in its outlook, which helps stabilize share price in the current volatile market.Since 99.37% of revenue is from China market, China TCM is less likely to be affected by trade war/geopolitical risks, and thus can be considered as safe haven asset. Its performance will rebound after 2024 low point
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Nikkei 225 Proposal for Dealing With Sony's (6758) Sony Finl Spinoff - A Non-Event but TOPIX Isn't
- UK: Some Workshy Start Looking
- Index Treatment of Sony (6758 JP)'s Spinoff of the Financial Services Business
- [Japan M&A] Carlyle Deal for TRYT (9164) - Great Exit for Speculators as HR Co Targets Are Desirable
- No, Hong Kong Won't Abandon The Peg
Top Unpaywalled Insights
More »- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- The Impact of Trump's Tariffs on China Healthcare - The Victims, And the Safe Haven Assets08 Apr 2025
- Goldlion Holdings (533 HK) Privatization - Updates on Valuation Outlook Based on 2024 Results07 Apr 2025
- China Healthcare Weekly (Apr.6) - SASAC to Encourage SOE M&A, WuXi AppTec Disposed XDC Shares Again06 Apr 2025
- China TCM (570.HK) - About the Profit Warning and the Valuation Outlook21 Jan 2025
- China Healthcare Weekly (Dec.8) - TCM VBP Update, GLP-1's Good Story Broke, China TCM's Sudden Rally08 Dec 2024
- China TCM (570.HK) Update - The Real Reason For the Deal Break and the Valuation Outlook05 Nov 2024
x